Just as PsA is multi-faceted, so too was Dr. Ritchlin’s lecture. He sought to help the audience understand the underlying mechanisms of the immune system that promote disease activity and the latest research on how to optimize therapy.
Many organizations have created guidelines for the management of PsA, such as the ACR and the National Psoriasis Foundation, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and EULAR. Each set of guidelines must be understood in the context of the data on which it was constructed. In his lecture, Dr. Ritchlin helped rheumatologists understand this information and how to make informed decisions on the part of their patients with PsA.
Jason Liebowitz, MD, is an assistant professor of medicine in the Division of Rheumatology at Columbia University Vagelos College of Physicians and Surgeons, New York.
References
- Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Nov;69(5):729–735.
- Ogdie A, Hur P, Liu M, et al. Effect of multidomain disease presentations on patients with psoriatic arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021 May;48(5):698–706.
- Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023 Jan;23(1):38–54.
- Myers B, Brownstone N, Reddy V, et al. The gut microbiome in psoriasis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2019 Dec;33(6):101494.
- Regierer A, Kiefer D, Schett G, et al. PsA patients receiving monotherapy with bDMARD/tsDMARD do not differ in clinical parameters from patients receiving bDMARD/tsDMARD in combination with MTX-data from RABBIT-SpA [OP0063]. Ann Rheum Dis. 2023;82:43.
- Jadon DR, Sengupta R, Nightingale A, et al. Axial disease in psoriatic arthritis study: Defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. 2017 Apr;76(4):701–707.
- Feagan BG, Sands BE, Sandborn WJ, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307–320.
